What's new? Log in Free sign up

PDS Biotechnology (PDSB) News and press releases

Company Profile

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's Intraday Session

Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool.

Oppenheimer Reiterates Outperform on PDS Biotechnology, Maintains $24 Price Target

News, Price Target, Reiteration, Analyst Ratings

Oppenheimer analyst Leland Gershell reiterates PDS Biotechnology (NASDAQ:PDSB) with a Outperform and maintains $24 price target.

Booz Allen Hamilton, Workday, Marvell Technology And Other Big Stocks Moving Higher On Friday

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Friday. Here are some big stocks recording gains in today’s session.

12 Health Care Stocks Moving In Friday's Pre-Market Session

Why Gap Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Oncorus, Inc. (NASDAQ: ONCR) shares rose 90% to $0.38 in pre-market trading after dropping around 17% on Thursday. Oncorus recently posted a narrower-than-expected quarterly loss.

Why PDS Biotech Shares Are Jumping Today

Biotech, News, Health Care, Movers, General

Tesla, Costco, Marvell, Ulta Beauty, PDS Biotechnology: Why These 5 Stocks Are Drawing Investor Attention

Equities, News, Markets

Oppenheimer Reiterates Outperform on PDS Biotechnology, Maintains $24 Price Target

News, Price Target, Reiteration, Analyst Ratings

Oppenheimer analyst Leland Gershell reiterates PDS Biotechnology (NASDAQ:PDSB) with a Outperform and maintains $24 price target.

PDS Biotechnology Q1 EPS $(0.32) Misses $(0.31) Estimate; Cash & Cash Equivalents Of Approximately $65.2M Sufficient To Fund Its Operations Into Q3 Of 2024

PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.31) by 3.23 percent. This is unchanged from the same period last year.

Earnings Scheduled For May 15, 2023

Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is projected to report earnings for its first quarter.

PDS Biotech To Present Updated Data At 2023 American Society Of Clinical Oncology Annual Meeting Highlighting Combination Of PDS0101 And KEYTRUDA In Head And Neck Cancer Patients

Biotech, News, Events, General

PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced the presentation of updated data

PDS Biotech Receives $1.4M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

News, Asset Sales

PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease announced the Company

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 price target.

Where PDS Biotechnology Stands With Analysts

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 price target.

PDS Biotech Looks to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA in Head and Neck Cancer in 2023

PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced that it has completed key

B. Riley Securities Reiterates Buy on PDS Biotechnology, Maintains $12 Price Target

News, Price Target, Reiteration, Analyst Ratings

B. Riley Securities analyst Kalpit Patel reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $12 price target.

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 price target.

Earnings Scheduled For March 28, 2023

Companies Reporting Before The Bell • Futu Holdings (NASDAQ:FUTU) is expected to report quarterly earnings at $0.70 per share on revenue of $237.12 million.

Press releases

From Benzinga Pro

PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients

Biotech, News, Press Releases, General

Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1%A disease control rate (disease

PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results

Earnings, Press Releases

Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- PDS

PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients

FLORHAM PARK, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and

PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

News, Health Care, Financing, Press Releases, General

FLORHAM PARK, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and

PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023

Biotech, News, Press Releases, General

FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and

PDS Biotech to Participate in Cantor's Future of Oncology Virtual Symposium

News, Press Releases

FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results

Biotech, Earnings, Press Releases, General

Successful meeting with FDA to discuss registrational pathway for triple combination of PDS0101, PDS0301, and a commercial immune checkpoint inhibitor100% (9/9) clinical response (>60% tumor shrinkage at mid-point

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.